Trials / Withdrawn
WithdrawnNCT03862690
A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria
A Prospective Non-interventional Study Investigating the Treatment Effect of NovoMix® 30 (Biphasic Insulin Aspart 30) in a Real World Adult Population With Type 2 Diabetes in Algeria
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to collect information about how NovoMix® 30 works in real world adult population with type 2 diabetes. Participants will get NovoMix® 30 as prescribed by the study doctor. The study will last for about 6-8 months. Participants will be asked questions about their health and their diabetes treatment as part of their study doctor's appointment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIAsp 30 | Participants will receive commercially available BIAsp 30 once daily (QD), twice daily (BID) or thrice daily (TID) for 24 weeks according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose. The decision to switch the patient to NovoMix® 30 is at the treating physician's discretion and independent from the decision to include the patient in the study. |
Timeline
- Start date
- 2020-05-28
- Primary completion
- 2021-06-28
- Completion
- 2021-06-28
- First posted
- 2019-03-05
- Last updated
- 2020-07-20
Locations
2 sites across 1 country: Algeria
Source: ClinicalTrials.gov record NCT03862690. Inclusion in this directory is not an endorsement.